Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

289 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Immunoengineering: how nanotechnology can enhance cancer immunotherapy.
Goldberg MS. Goldberg MS. Cell. 2015 Apr 9;161(2):201-4. doi: 10.1016/j.cell.2015.03.037. Cell. 2015. PMID: 25860604 Review.
Biotargeted nanomedicines for cancer: six tenets before you begin.
Goldberg MS, Hook SS, Wang AZ, Bulte JW, Patri AK, Uckun FM, Cryns VL, Hanes J, Akin D, Hall JB, Gharkholo N, Mumper RJ. Goldberg MS, et al. Nanomedicine (Lond). 2013 Feb;8(2):299-308. doi: 10.2217/nnm.13.3. Nanomedicine (Lond). 2013. PMID: 23394158 Free PMC article.
siRNA delivery for the treatment of ovarian cancer.
Goldberg MS. Goldberg MS. Methods. 2013 Sep 15;63(2):95-100. doi: 10.1016/j.ymeth.2013.01.007. Epub 2013 Feb 10. Methods. 2013. PMID: 23403216 Review.
Dual-layer surface coating of PLGA-based nanoparticles provides slow-release drug delivery to achieve metronomic therapy in a paclitaxel-resistant murine ovarian cancer model.
Amoozgar Z, Wang L, Brandstoetter T, Wallis SS, Wilson EM, Goldberg MS. Amoozgar Z, et al. Among authors: goldberg ms. Biomacromolecules. 2014 Nov 10;15(11):4187-94. doi: 10.1021/bm5011933. Epub 2014 Oct 7. Biomacromolecules. 2014. PMID: 25251833
Targeting myeloid cells using nanoparticles to improve cancer immunotherapy.
Amoozgar Z, Goldberg MS. Amoozgar Z, et al. Among authors: goldberg ms. Adv Drug Deliv Rev. 2015 Aug 30;91:38-51. doi: 10.1016/j.addr.2014.09.007. Epub 2014 Oct 2. Adv Drug Deliv Rev. 2015. PMID: 25280471 Review.
Cosilencing of PKM-2 and MDR-1 Sensitizes Multidrug-Resistant Ovarian Cancer Cells to Paclitaxel in a Murine Model of Ovarian Cancer.
Talekar M, Ouyang Q, Goldberg MS, Amiji MM. Talekar M, et al. Among authors: goldberg ms. Mol Cancer Ther. 2015 Jul;14(7):1521-31. doi: 10.1158/1535-7163.MCT-15-0100. Epub 2015 May 11. Mol Cancer Ther. 2015. PMID: 25964202 Free PMC article.
The PARP1 inhibitor BMN 673 exhibits immunoregulatory effects in a Brca1(-/-) murine model of ovarian cancer.
Huang J, Wang L, Cong Z, Amoozgar Z, Kiner E, Xing D, Orsulic S, Matulonis U, Goldberg MS. Huang J, et al. Among authors: goldberg ms. Biochem Biophys Res Commun. 2015 Aug 7;463(4):551-6. doi: 10.1016/j.bbrc.2015.05.083. Epub 2015 Jun 3. Biochem Biophys Res Commun. 2015. PMID: 26047697
Decitabine Enhances Lymphocyte Migration and Function and Synergizes with CTLA-4 Blockade in a Murine Ovarian Cancer Model.
Wang L, Amoozgar Z, Huang J, Saleh MH, Xing D, Orsulic S, Goldberg MS. Wang L, et al. Among authors: goldberg ms. Cancer Immunol Res. 2015 Sep;3(9):1030-41. doi: 10.1158/2326-6066.CIR-15-0073. Epub 2015 Jun 8. Cancer Immunol Res. 2015. PMID: 26056145
Improving cancer immunotherapy with DNA methyltransferase inhibitors.
Saleh MH, Wang L, Goldberg MS. Saleh MH, et al. Among authors: goldberg ms. Cancer Immunol Immunother. 2016 Jul;65(7):787-96. doi: 10.1007/s00262-015-1776-3. Epub 2015 Dec 8. Cancer Immunol Immunother. 2016. PMID: 26646852 Review.
Surface modulation of polymeric nanocarriers enhances the stability and delivery of proteins and small molecules.
Amoozgar Z, Goldberg MS. Amoozgar Z, et al. Among authors: goldberg ms. Nanomedicine (Lond). 2017 Apr;12(7):729-743. doi: 10.2217/nnm-2016-0375. Epub 2017 Mar 21. Nanomedicine (Lond). 2017. PMID: 28322107
289 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page